. 2015 Feb 7;10:35. doi: 10.1186/s13014-015-0343-6

Table 2.

Univariate analysis (upper column) and multivariate analysis (lower column) using Cox regression

Variables	In-field control			Locoregional control			Freedom from distant metastasis			Freedom from progression
Variables	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI
Attachment status: broad attachment vs. others	<0.01*	11.5	2.42-81.5	<0.01*	4.60	1.91-10.8	0.01*	3.02	1.22-7.19	<0.01*	3.78	1.87-7.40
Gender: female vs. male	0.89	1.11	0.15-5.20	0.29	0.57	0.16-1.54	0.57	1.29	0.49-3.03	0.54	0.79	0.35-1.62
Diagnosis: pathological vs. clinical	0.17	3.59	0.60-68.1	0.15	2.00	0.78-6.13	0.19	1.81	0.75-5.09	0.11	1.79	0.87-4.04
Tumor diameter (cm): per 1 cm increase	<0.01*	3.71	1.47-9.72	<0.01*	2.25	1.30-3.83	<0.01*	2.01	1.19-3.33	<0.01*	2.02	1.32-3.07
Perfomance status: 0-1 vs. 2-3	0.97	0.96	0.15-18.5	0.88	1.09	0.36-4.71	0.38	1.81	0.52-11.3	0.48	1.42	0.56-4.81
SBRT dose (BED₁₀): > 102 Gy₁₀ vs. ≤ 102 Gy₁₀	0.02*	0.13	0.01-0.79	0.59	1.25	0.54-3.05	0.88	0.94	0.45-2.02	0.77	0.90	0.47-1.75
Prescription: isocenter vs. D95	0.53	1.88	0.30-36.3	0.94	0.96	0.35-3.01	0.79	0.88	0.35-2.48	0.27	0.64	0.30-1.45
Attachment status: broad attachment vs. others	0.15	4.00	0.59-35.6	0.02*	3.08	1.15-8.27	0.19	1.93	0.70-5.29	0.01*	2.66	1.21-5.73
Tumor diameter (cm): per 1 cm increase	0.04*	3.65	1.00-14.1	0.12	1.67	0.86-3.10	0.09	1.68	0.91-3.00	0.06	1.59	0.96-2.55
SBRT dose (BED₁₀): > 102 Gy₁₀ vs. ≤ 102 Gy₁₀	0.02*	0.10	0.01-0.75	n.s.			n.s.			n.s

Abbreviations: D95, doses covering 95% of the planning target volume; BED, biological effective dose; HR, hazard ratio; CI, confidence interval; n.s, not significant. *p < 0.05.